Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozinameran + riltozinameran (BioNTech SE, 0416d4)
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
BNT162b2 bivalent (WT/OMI BA.1) is a nucleoside-modified mRNA vaccine developed by BioNTech and Pfizer to provide protection against COVID-19. It is a bivalent formulation containing 15 micrograms of mRNA encoding the spike protein of the original SARS-CoV-2 (Wuhan-Hu-1) and 15 micrograms of mRNA encoding the spike protein of the Omicron BA.1 variant. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver the mRNA into host cells, where it is translated into spike proteins that trigger an immune response, including the production of neutralizing antibodies and activation of T cells. This bivalent version was developed as a booster to address waning immunity and the emergence of the Omicron variant.
- Brand names
- Comirnaty Original/Omicron BA.1
- Other names
- BNT162b2 (Original/Omicron BA.1)tozinameran/riltozinameranPfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.1)
02
Targets
ACE2 (Angiotensin-converting enzyme 2)T-cell receptor and B-cell receptor recognizing SARS-CoV-2 spike proteinPRR (Pattern recognition receptors)SARS-CoV-2 spike
Beyond the preview
Go deeper on tozinameran + riltozinameran (BioNTech SE, 0416d4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozinameran + riltozinameran (BioNTech SE, 0416d4).